Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration announced a shortage of amphetamine mixed salts Oct. 12 and said ... Adderall is made from amphetamine mixed salts and Concerta is made from methylphenidate. ...
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required, by section 202 of that Act, for substances to be placed in this schedule: The drug or other substance has a high potential for abuse.
Methylphenidate is used for the treatment of attention deficit hyperactivity disorder (ADHD). [30] The dosage may vary and is titrated to effect, with some guidelines recommending initial treatment with a low dose. [31] Methylphenidate is available in both immediate-release and modified-release formulations to provide a sustained release of the ...
Most stimulants are amphetamine-based (Adderall, Vyvanse) or methylphenidate-based (Concerta, Ritalin), and come in immediate-release (short-acting) or extended-release (long-acting) formulations.
Subsequently, amphetamine was used in the treatment of narcolepsy, obesity, hay fever, orthostatic hypotension, epilepsy, Parkinson's disease, alcoholism and migraine. [12] [15] The "reinforcing" effects of substituted amphetamines were quickly discovered, and the misuse of substituted amphetamines had been noted as far back as 1936. [15]
Amphetamines and methylphenidate are classified by the Drug Enforcement Administration as Schedule II controlled substances, the same designation given to cocaine, OxyContin and fentanyl.
Despite having a similar therapeutic mechanism of action as first-line medications containing amphetamine, the prescription of dextromethamphetamine for ADHD is rare due its relatively greater reinforcing potential, in addition to the comparable efficacy and presumably greater safety of methylphenidate and amphetamine.
This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved.